Abstract:Lysine-specific demethylase 1 (LSD1), the first identified histone demethylase, is a flavin-dependent amine oxidase which specifically demethylates mono-or dimethylated H3K4 and H3K9 via a redox process. It participates in a broad spectrum of biological processes and is of high importance in cell proliferation, adipogenesis, spermatogenesis, chromosome segregation and embryonic development. To date, as a potential drug target for discovering anti-tumor drugs, the medical significance of LSD1 has been greatly appreciated. However, the catalytic mechanism for the rate-limiting reductive half-reaction in demethylation remains controversial. By employing a combined computational approach including molecular modeling, molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculations, the catalytic mechanism of dimethylated H3K4 demethylation by LSD1 was characterized in details. The three-dimensional (3D) model of the complex was composed of LSD1, CoREST, and histone substrate. A 30-ns MD simulation of the model highlights the pivotal role of the conserved Tyr761 and lysine-water-flavin motif in properly orienting flavin adenine dinucleotide (FAD) with respect to substrate. The synergy of the two factors effectively stabilizes the catalytic environment and facilitated the demethylation reaction. On the basis of the reasonable consistence between simulation results and available mutagenesis data, QM/MM strategy was further employed to probe the catalytic mechanism of the reductive half-reaction in demethylation. The characteristics of the demethylation pathway determined by the potential energy surface and charge distribution analysis indicates that this reaction belongs to the direct hydride transfer mechanism. Our study provides insights into the LSD1 mechanism of reductive half-reaction in demethylation and has important implications for the discovery of regulators against LSD1 enzymes.

Lysine-specific Histone Demethylase 1 (LSD1): A Potential Molecular Target for Tumor Therapy

Therapeutic potential of targeting LSD1/ KDM1A in cancers

Targeting LSD1 in cancer: Molecular elucidation and recent advances

Pharmacological Inhibition of LSD1 for Cancer Treatment

Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential

LSD1 Coordinates with the SIN3A/HDAC Complex and Maintains Sensitivity to Chemotherapy in Breast Cancer.

Prominent Role of Histone Lysine Demethylases in Cancer Epigenetics and Therapy

Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks

Catalytic Mechanism Investigation Of Lysine-Specific Demethylase 1 (Lsd1): A Computational Study

LSD1 Knockdown Reveals Novel Histone Lysine Methylation in Human Breast Cancer MCF-7 Cells

LSD1: an Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

LSD1 inhibitors for anticancer therapy: a patent review (2017-present)

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

LSD1 is a promising target to treat cancers by modulating cell stemness

Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

Novel Histone Demethylase LSD1 Inhibitors Selectively Target Cancer Cells with Pluripotent Stem Cell Properties.

The Histone Demethylase LSD1 is a Novel Oncogene and Therapeutic Target in Oral Cancer.

Inhibition of Lysine‐specific Histone Demethylase LSD1 Suppresses Melanoma Growth